Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
PMV Pharmaceuticals, Inc
BeOne Medicines
Monte Rosa Therapeutics, Inc
Neonc Technologies, Inc.
Wake Forest University Health Sciences
MacroGenics
MacroGenics
ImmunityBio, Inc.
DualityBio Inc.
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Janux Therapeutics
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Incyte Corporation
National Institutes of Health Clinical Center (CC)
University of Virginia
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
Shanghai Public Health Clinical Center
TransThera Sciences (Nanjing), Inc.
NRG Oncology
Klus Pharma Inc.
University of California, San Francisco
Theratechnologies
Stanford University
Seagen Inc.
Cybrexa Therapeutics
Sotio Biotech Inc.
Carisma Therapeutics Inc
AstraZeneca
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Xencor, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
Evopoint Biosciences Inc.
Zhejiang University
University of Florida
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
Jules Bordet Institute